Novel all trans-retinoic acid derivatives: Cytotoxicity, inhibition of cell cycle progression and induction of apoptosis in human cancer cell lines

Article abstract of DOI:10.3390/molecules20058181

Owing to the pharmacological potential of ATRA (all trans-retinoic acid), a series of retinamides and a 1-(retinoyl)-1,3-dicyclohexylurea compound were prepared by reacting ATRA with long chain alkyl or alkenyl fatty amines by using a 4-demethylaminopyrid

Full text of DOI:10.3390/molecules20058181

Molecules 2015, 20, 8181-8197; doi:10.3390/molecules20058181
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
Novel All Trans-Retinoic Acid Derivatives: Cytotoxicity,
Inhibition of Cell Cycle Progression and Induction of Apoptosis
in Human Cancer Cell Lines
1
1
2,3
Ebtesam Saad Al-Sheddi , Mai Mohammad Al-Oqail , Quaiser Saquib ,
2
,3
2,3
2
Maqsood Ahmed Siddiqui , Javed Musarrat , Abdulaziz Ali Al-Khedhairy and
1,
Nida Nayyar Farshori *
1
Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 11495,
Saudi Arabia; E-Mails: ebtesam.saad@yahoo.com (E.S.A.-S.); maioqail@hotmail.com (M.M.A.-O.)
2
Zoology Department, College of Science, King Saud University, Riyadh 11451, Saudi Arabia;
E-Mails: quaiser.saquib0@gmail.com (Q.S.); maqsoodahmads@gmail.com (M.A.S.);
musarratj1@yahoo.co.in (J.M.); kedhairy@yahoo.com (A.A.A.-K.)
3
Al-Jeraisy Chair for DNA Research, College of Science, King Saud University, Riyadh 11451,
Saudi Arabia
*
Author to whom correspondence should be addressed; E-Mail: nidachem@gmail.com;
Tel.: +966-537362212; Fax: +966-1180-52785.
Academic Editor: Jean Jacques Vanden Eynde
Received: 5 February 2015 / Accepted: 29 April 2015 / Published: 7 May 2015
Abstract: Owing to the pharmacological potential of ATRA (all trans-retinoic acid),
a series of retinamides and a 1-(retinoyl)-1,3-dicyclohexylurea compound were prepared by
reacting ATRA with long chain alkyl or alkenyl fatty amines by using a
4
-demethylaminopyridine (DMAP)-catalyzed N,N′-dicyclohexylcarbodiimide (DCC)
coupling. The successful synthesis of the target compounds was demonstrated using a range
of spectroscopic techniques. The cytotoxicity of the compounds was measured along with
their ability to induce cell cycle arrest and apoptosis in human cancer cell lines MCF-7
(
breast cancer) and HepG2 (liver cancer) and normal human cell line HEK293 (embryonic
kidney). The results of cytotoxicity and flow cytometry data showed that the compounds had
a moderate to strong effect against MCF-7 and HepG2 cells and were less toxic to HEK293
cells. N-oleyl-retinamide was found to be the most potent anticancer agent and was more
effective against MCF-7 cells than HepG2 cells.

Molecules 2015, 20
Keywords: all trans-retinoic acid; anticancer activity; apoptosis; cell cycle arrest;
8182
cytotoxicity
1
. Introduction
Non-contagious diseases, such as cancer, are responsible for 64% of deaths worldwide [1]. Cancer
involves an unrestrained, rapid increase in the number of diseased cells, which affects healthy cells
adversely, a process that ultimately leads to the death of the cancer patient. Differentiation therapy, first
proposed by Sachs [2], has been extensively studied as a means of treating cancer. All trans-retinoic acid
(
ATRA) is known to induce differentiation in various cancer cells [3–6]. The cytotoxic responses of
ATRA against various cancerous cell lines have also been reported [7]. The physiological activity of
retinoids is due to their interaction with two types of receptors: the retinoic acid receptors (RARα, RARβ
and RARγ) and the retinoid X receptors (RXRα, RXRβ and RXRγ). Retinoids bind to RAR/RXR
heterodimers at the retinoic acid response element (RARE), induce conformational changes and thereby
lead to transcriptional activation of the target genes [8]. However, the clinical applications of ATRA
have been limited by epigenetic changes that can eventually make cells resistant. Therefore, it is vital to
improve the effectiveness of ATRA through structural modifications.
By chemically modifying the polar carboxylic acid group in ATRA, new retinoids with high potency
and low toxicity can be obtained [9–12]. Furthermore, the attachment of fatty acids may lead to drugs
with enhanced stability, solubility, cellular uptake and shorter half-lives. For example, linking paclitaxel
to a natural fatty acid was shown to increase its accumulation in tumors [13], and the fatty acylamide
derivative of doxorubicin was found to be more effective than the unmodified parent compound in
inhibiting the proliferation of ovarian and colon cancer cells [14]. In addition, conjugating fatty acyl
groups to cytarabine improved its cellular uptake [15].
In view of the above-mentioned examples, it was speculated that the effectiveness of ATRA could be
improved by conjugating its polar carboxylic acid group to various long chain fatty acid amines. These
novel hybrids were prepared and then tested against two human cancer cell lines—MCF-7 (breast
cancer) and HepG2 (liver cancer)—to determine their cytotoxicity, their ability to inhibit cell cycle
progression and their effect on apoptosis. In addition, the cytotoxic effect of the compounds against the
normal cell line HEK293 (human embryonic kidney) was also evaluated.
2
. Results and Discussion
Vitamin A, its derivatives and its active metabolite ATRA play a pivotal role in cell growth,
differentiation, apoptosis and other related processes [16,17]. Although the retinoids are potential
chemotherapeutic and chemopreventive agents [18,19], their usefulness is currently limited by their side
effects [20–24]. Therefore, the synthesis of new retinoid hybrids is vital. This work describes the
synthesis, characterization, cytotoxicity, effect on cell cycle progression and apoptotic effect of various
derivatives of ATRA.

Molecules 2015, 20
.1. Chemistry
8183
2
The chemical reaction sequence has been outlined in Scheme 1. ATRA reacts with long chain fatty
amines in the presence of N,N′-dicyclohexylcarbodiimide (DCC) and 4-demethylaminopyridine
DMAP) in DMSO to yield the amidic derivatives 3a, 3b and the 1-substituted-1,3-dicyclohexylurea
(
derivative 4 of all trans-retinoic acid (ATRA).
Scheme 1. Reaction scheme showing the synthesis of novel all trans-retinoic acid (ATRA)
derivatives. Compounds 3a, 3b and 4 were prepared by a 4-demethylaminopyridine
(
DMAP)-catalyzed N,N′-dicyclohexylcarbodiimide (DCC) coupling reaction in DMSO.
During DCC-catalyzed amide synthesis, the side product is dicyclohexylurea [25]. However, under
suitable reaction conditions, a satisfactory yield of both an amide derivative and an acyl urea derivative
can be achieved. The optimum conditions were determined using various ratios of reagent and catalyst.
The generality and scope of the synthetic procedure was demonstrated using both a long chain
alkylamine and a long chain alkenyl amine. The structure of compounds 3a, 3b and 4 was established
using their spectral data.
−
1
The IR of compound 3b revealed characteristic absorption bands at 3302 (N-H) and 1633 cm (C=O).
1
13
H-NMR was informative, and characteristic resonances at 7.25 (s, 1H, NH), 6.79 (dd, 1H, C H), 6.23
9
12
10
16
14
30
(
m, 2H, C H, C H), 6.09 (d, 1H, C H), 5.74 (s, 1H, C H), 5.65 (s, 1H, C H) and 5.30 ppm (m, 2H, C H
31
13
=
C H) were observed. These were correlated with resonances in the C-NMR spectrum at 140.65,
1
37.20, 130.32, 130.04, 129.58, 125.74 and 126.10 ppm. Besides these, a few other significant carbon
signals, such as a characteristic peak at δ 166.80 (C=O), were observed. Compounds 3a and 4 were
c
characterized in a similar manner, and these spectral studies indicated that the nature of the fatty amine
did not significantly influence the chemical shifts of the proton and carbon signals of the ATRA moiety.
Compound 4 was also characterized using spectral data. In the IR spectrum, characteristic bands at
−
1
1
3
310 (N-H), 1638 (C=O) and 1227 cm (C-N) were observed. The H-NMR showed resonances at 7.29

Molecules 2015, 20
8184
1
3
9
12
10
16
(
(
s, 1H, NH), 6.72 (dd, 1H, C H), 6.27 (m, 2H, C H, C H), 6.19 (d, 1H, C H), 5.79 (s, 1H, C H), 5.62
1
4
s, 1H, C H), 3.84–3.80 (m, 1H, CH of C
6
H
11) and 3.63–3.61 ppm (m, 1H, CH of C H11). These were
6
1
3
further correlated with the signals observed in the C-NMR spectrum at 140.65, 137.24, 130.28, 127.48,
1
26.19, 125.70, 50.7 and 49.8 ppm.
2.2. Cytotoxicity
The cytotoxicity of compounds 3a, 3b and 4 was assessed using MTT and neutral red uptake
(
NRU) assays.
2.2.1. MTT Assay
The key results obtained using the MTT assay for ATRA and compounds 3a, 3b and 4 in MCF-7,
HepG2 and HEK293 cells are shown in Table 1 and Figure 1A–C, respectively. A concentration-dependent
decrease in cell viability was observed in MCF-7 and HepG2 cells following 24 h of exposure to
compounds 3a, 3b and 4. The cell viability at doses of 250, 500 and 1000 μM of compound 3a was
measured to be 80%, 8% and 5% in MCF-7 cells and 87%, 7% and 7% in HepG2 cells, respectively.
Following treatment with 250-, 500- and 1000-μM doses of compound 4, cell viability was measured to be
5
%, 5% and 4% in MCF-7 cells and 7%, 6% and 6% in HepG2 cells, respectively. For compound 3b, a
decrease in the viability of MCF-7 and HepG2 cells was observed even after treatment with a dose of 25 μM
Cell viability following doses of 25, 50, 100, 250, 500 and 1000 μM of compound 3b was recorded as
1
0%, 7%, 6%, 6%, 5% and 5% in MCF-7 cells (Figure 1A) and 38%, 9%, 7%, 7%, 6% and 5% in HepG2
cells (Figure 1B), respectively. Compounds 3a and 3b were both less toxic to HEK293 cells than to
MCF-7 and HepG2 cells. Compound 4 did not cause any cytotoxicity at lower doses in HEK293 cells,
except at a dose of 1000 μM (Figure 1C). The viability of HEK293 cells following treatment with doses
of 250, 500 and 1000 μM of compounds 3a, 3b and 4 was measured to be 88%, 31% and 19% (3a),
1
5
6%, 15% and 13% (3b), and 100%, 100% and 77% (4), respectively (Figure 1C). Compound 4 at 25,
0, 100, 250 and 500 M doses was found to induced cytotoxicity in cancer cells (MCF-7 and HepG2),
but was found non-cytotoxic towards normal cells (HEK293). Similarly, compound 3b showed
cytotoxicity at a dose of 25 μM in MCF-7 and HepG2 cells, but not in HEK293 cells. The results also
indicated that ATRA was not effective at concentrations ranging from 10–50 μM (Table 1).
Table 1. Cytotoxicity assessments of all trans-retinoic acid (ATRA) by MTT assay in MCF-7
cells, HepG2 cells and HEK293 cells. The cells were exposed to different concentrations of
ATRA for 24 h. Values are the mean ± SE of three independent experiments.
Concentrations of ATRA MCF-7 Cells HepG2 Cells HEK293 Cells
Control
100 ± 5.0
104.0 ± 7.6
99.0 ± 2.4
97.0 ± 4.3
93.9 ± 7.4
90.5 ± 2.9
86.8 ± 5.0
83.0 ± 5.8
100 ± 1.6
105.2 ± 1.7
102.5 ± 4.3
101.2 ± 3.2
98.2 ± 3.4
97.6 ± 2.2
95.2 ± 6.0
91.9 ± 2.3
100 ± 4.0
102.6 ± 5.6
102.2 ± 4.0
100.2 ± 3.6
99.1 ± 4.2
97.2 ± 2.5
98.4 ± 3.4
94.6 ± 4.9
1
2
5
0 μM
5 μM
0 μM
1
2
5
00 μM
50 μM
00 μM
1
000 μM

Molecules 2015, 20
8185
Figure 1. Cytotoxicity assessments by MTT assay in (A) MCF-7 cells, (B) HepG2 cells and
C) HEK293 cells. The cells were exposed to different concentrations of compounds 3a, 3b
and 4 for 24 h. Values are the mean ± SE of three independent experiments.
(
2.2.2. NRU Assay
The key results obtained using the NRU assay are summarized in Figure 2A–C. A dose-dependent
decrease in the cell viability of MCF-7 and HepG2 cells was observed following treatment with
compounds 3a, 3b and 4 for 24 h. The percentage of cell viability after 250-, 500- and 1000-μM doses
of compound 3a was measured to be 81%, 10% and 6% in MCF-7 cells and 70%, 9% and 8% in HepG2
cells, respectively. Following treatment with 250-, 500- and 1000-μM doses of compound 4, the cell
viability was found to be 6%, 6% and 5% in MCF-7 cells and 8%, 7% and 7% in HepG2 cells,
respectively. For compound 3b, a decrease in the cell viability of MCF-7 and HepG2 was recorded even
after treatment with a 25-μM dose. The cell viability following treatment with 25-, 50-, 100-, 250-, 500-
and 1000-Μm doses of compound 3b was recorded as 11%, 8%, 7%, 6%, 6% and 5% in MCF-7 cells
(
Figure 2A) and 40%, 12%, 8%, 8%, 7% and 6% in HepG2 cells (Figure 2B), respectively. However, in
HEK293 cells, the cell viability after treatment with 250-, 500- and 1000-μΜ doses of compounds 3a,
b and 4 was found to be 92%, 34% and 18% (3a), 21%, 19% and 13% (3b) and 100%, 100% and 46%
4), respectively (Figure 2C). As in the MTT assay, compound 3a was found to be less cytotoxic than
b, and compound 4 did not cause any cytotoxic affect except at a 1000-μM concentration, as compared
3
(
3
to the untreated control (Figure 2C). Compound 4 at 25-, 50-, 100-, 250- and 500-μM doses was also
found to induce cytotoxicity in cancer cells (MCF-7 and HepG2) by the NRU assay, but was found
non-cytotoxic towards normal cells (HEK293). Compound 3b also was found to induce cytotoxicity at
a dose of 25 μM in MCF-7 and HepG2 cells, but not in normal HEK293 cells by the NRU assay.

Molecules 2015, 20
8186
Figure 2. Cytotoxicity assessments by the neutral red uptake (NRU) assay in (A) MCF-7
cells, (B) HepG2 cells and (C) HEK293 cells. The cells were exposed to different
concentrations of compounds 3a, 3b and 4 for 24 h. Values are the mean ± SE of three
independent experiments.
The results of the MTT and NRU assays showed that compound 3b exhibited the highest cytotoxicity
against both types of cancer cells, and compound 4 was the second most effective. Compound 3a was
found to be the least effective, and significant cytotoxicity was observed only at higher concentrations,
i.e., 250 μM or above. The MTT assay was a more effective representative of cytotoxicity than the NRU
assay. It has previously been reported that the results can vary depending on the cytotoxicity assay used [26].
2
.3. Morphological Analysis in MCF-7, HepG2 and HEK293 Cells
The morphological changes observed in cells that were exposed to compounds 3a, 3b, and 4 for
2
4 h are shown in Figure 3A–C. Changes in morphology were observed using a phase contrast inverted
microscope. The cells indicate that the most prominent effects after the exposure of compounds and
changes in their morphology were found to be concentration dependent. Cells exposed to higher doses
of compounds lose their normal morphology and shape; these cells become more rounded and less
adherent than the control.

Molecules 2015, 20
8187
Figure 3. Morphological changes in (A) MCF-7 cells, (B) HepG2 cells and (C) HEK293
cells. The cells were exposed to different concentrations of compounds 3a, 3b and 4 for
4 h. Images were taken using an inverted phase contrast microscope at 20× magnification.
2
2
.4. Flow Cytometry Analysis
In order to evaluate the anticancer properties of compounds 3a, 3b and 4, we studied the cell death of
HepG2 and MCF-7 cells. Cell cycle analysis of cells treated with compounds 3a, 3b and 4 indicated an
increase in the apoptotic subG population after 24 h of exposure (Figures 4 and 5). With a 10.4%
background level of apoptosis in the HepG2 control, compound 3a at its lowest treatment concentration
250 µM) clearly induced a great deal of cell death, as evidenced by the appearance of 99.8% dead cells
in the sub-G phase (Supplementary Figure S1). HepG2 cells exposed to low doses of compound 4
exhibited a pattern typical of G /M arrest. In control cells, 21.5% of control cells were in the G /M phase;
after treatment with 10- and 25-µM doses of compound 4, 30.8% and 32.2% cells were in the G /M
phase. At the highest concentration (50 µM), compound 4 led to the transition of G /M-arrested cells
24.5%) to the apoptotic phase sub-G1 (17.9%). A similar pattern of G /M arrest was observed in HepG2
cells treated with compound 3b. Following treatment with low doses (10 and 25 µM) of 3b, 22.4% and
5.2% of cells were in the G /M phase compared to 17.8% in the untreated control. Compound 3b at the
highest concentration (50 µM) induced a stronger apoptotic response with 37.4% cells in the sub-G
1
(
1
2
2
2
2
(
2
2
2
1
phase (Supplementary Figure S1). Compared to HepG2, a different change in cell cycle progression was
observed in MCF-7 cells (Figure 5). Cells exposed to 250- and 500-µM doses of compound 3a had
2
2.7% and 62.1% cells in the sub-G
1
phase, while 91.1% cells were in the sub-G
1
apoptotic phase
following treatment with a 1000-µM dose. Compounds 3b and 4 at 50 µM significantly induced

Molecules 2015, 20
8188
apoptosis in MCF 7 cells as evidenced by the 76.5% and 32.1% of cells in the sub-G1 phase, respectively
Figure S2). However, low concentrations of compound 3b or 4 did not induce G /M arrest in MCF-7.
(
2
Figure 4. Flow cytometry images of treated HepG2 cells. Flow cytometry images show
changes in cell cycle progression in HepG2 cells exposed to compounds 3a, 3b and 4 for
2
4 h. Sub-G1 indicates the cells undergoing apoptosis/necrosis and G2/M indicates the cell
cycle arrest.
Analysis of the effect of compound 3a on HepG2 and MCF-7 cells suggests that compound 3a
preferentially induces apoptosis in HepG2 cells at a concentration of 250 µM. On the other hand, we
observed more cell death in HepG2 and MCF-7 cells with low concentrations of 3b and 4. Compounds
3
b and 4 killed HepG2 cells predominantly by arresting them in the G
apoptosis. Compounds 4 and 3b kill significant numbers of MCF-7 cells by inducing apoptotic/necrotic
events. The appearance of a sub-G peak in the cell cycle analysis after the concentration of
2
/M phase, which is followed by
1
compounds 4 and 3b was increased suggests the upregulation of the early and late apoptotic/necrotic
pathway, which might be induced by a change in mitochondrial and lysosomal function [27,28].
Additionally, HepG2 cells underwent G /M arrest following treatment with compound 4, reflecting the
2
strong possibility of heavy DNA damage and failure of the DNA repair machinery in cells. It is known
that the cellular DNA repair mechanisms are highly conserved [29] and that extensive DNA damage
may lead to cell-cycle arrest and cell death [30,31].

Molecules 2015, 20
8189
Figure 5. Flow cytometry images of treated MCF-7 cells. Flow cytometry images depicting
changes in cell cycle progression in MCF-7 cells exposed to compounds 3a, 3b and 4 for
4 h. Sub-G1 indicates the cells undergoing apoptosis/necrosis.
2
2
.5. Apoptosis/Necrosis Assessment Using Annexin V-PE and 7-AAD in HepG2 and MCF 7 Cells
The flow cytometry data with Annexin V-PE (phycoerythrin) and 7-aminoactinomycin D (7-AAD)
clearly demonstrated that compounds 3a, 3b and 4 predominantly trigger cell death by initiating early
and late apoptotic processes with simultaneous transformation into the necrotic phase. Cell death induced
by compounds 3a, 3b and 4 was further confirmed using the Annexin V-PE and 7-AAD apoptotic assays.
The results are represented in a scatter plot, which represents the fluorescence generated by Annexin
V-PE interacting with phosphatidylserine on the plasma membrane of apoptotic/necrotic cells and the
specific staining of necrotic cells with 7-AAD dye. Based on the Annexin V-PE and 7-ADD staining,
more than 91.9% of HepG2 control cells were found alive with 0.5%, 5.8% and 0.2% of cells classified
as being in the early, late and necrotic stages. Exposure of HepG2 cells to 250-, 500- and 1000-µM doses
of compound 3a resulted in the induction of necrosis, which is represented by a shift of 17.9%, 71.2%
and 97.9% of the cellular population into the upper left quadrant (Annexin V−/7-AAD+) of the plot,
which represents necrotic cells (Figure 6). HepG2 cells that were exposed to low concentrations of 25
and 50 µM of compound 4 induced late apoptosis with an increase of 7.35% and 11% of cells in the
upper right quadrant (Annexin V+/7-AAD+), which represents late apoptotic cells. In contrast, the
exposure of HepG2 cells to 10-, 25- and 50-µM doses of compound 3b induced a concentration-dependent
increase of 8.1%, 11.4% and 72.8% of cells in the late apoptotic quadrant. In addition, the highest

Molecules 2015, 20
8190
concentration (50 µM) of compound 3b shifted 14.6% of cells into the upper left necrotic quadrant
Figure 6).
(
Figure 6. Annexin V-PE (phycoerythrin) and 7-AAD (7-aminoactinomycin D) assay
following treatment of HepG2 cells. Bivariate flow cytometry analysis of HepG2 cells
treated with compounds 3a, 3b and 4. Early apoptotic, late apoptotic and necrotic cells
following 24 h treatment are shown by the scatter plots.
Compared to HepG2, the Annexin-V results of MCF-7 cells further validated its unique response
towards compounds 3a, 3b and 4. MCF-7 cells exposed to doses of 250, 500 and 1000 µM of compound
a exhibited only 3.0%, 36.8% and 74.6% of cells in the quadrant representing necrotic cells (Figure 7).
3
Exposure to compound 4 resulted in the shift of MCF-7 cells towards the lower right quadrant (Annexin
V+/7-AAD−), indicating the onset of the early apoptotic phase. After doses of 10, 25 and 50 µM of
compound 4, 3.9%, 7.2% and 22.8% of cells were observed in the lower right quadrant (Figure 7).
Likewise, MCF-7 cells that were exposed to low doses of compound 3b (10 and 25 µM) also induced
early apoptotic events as evidenced by the appearance of 9.5% and 15.9% of cells in the lower right
quadrant. At the highest concentration (50 µM) of 3b, 60.9% and 20.7% of MCF-7 cells gradually shifted
to the late apoptotic quadrant and the necrotic quadrant (Figure 7). Compared to compound 4, compound
3
b significantly increased the number of early apoptosis events observed in the Annexin V+/7-AAD−
quadrant, which signifies the disintegration of the plasma membrane and externalization of

Molecules 2015, 20
8191
phosphatidylserine (PS), an event indicative of early apoptosis [32–34]. However, the appearance of a
significant population of late apoptotic cells suggests the complete loss of the cell membrane integrity,
eventually causing cell death due to necrosis in compound 3b-exposed cancerous cells. Overall, our flow
cytometry data suggests that compound 3b possesses a greater anticancer activity in MCF-7 cells than
in HepG2 cells.
Figure 7. Annexin V-PE (phycoerythrin) and 7-AAD (7-aminoactinomycin D) assay
following treatment of MCF-7 cells. Bivariate flow cytometry analysis of MCF-7 cells
treated with compounds 3a, 3b and 4. Early apoptotic, late apoptotic and necrotic cells
following 24 h treatment are shown by the scatter plots.
3
. Experimental Section
3
.1. Reagents
ATRA, undecylamine, octadecylamine, oleylamine, N,N'-dicyclohexylcarbodiimide (DCC),
4
-dimethylaminopyridine (DMAP) and all other chemicals were purchased from Sigma, St. Louis, MO,
USA. For thin-layer chromatography (TLC), Silica Gel F254 plates, Merck, NJ, USA (20 × 5cm) were
used. The plates were eluted using a mixture of petroleum ether, CHCl and CH COOH (70:30:1). Silica
3
3
gel 230–400 mesh (Merck, NJ, USA) was used for column chromatography. Dulbecco’s Modified
Eagle’s Medium (DMEM), antibiotic/antimycotic solutions and fetal bovine serum (FBS) were obtained
from Invitrogen, Life Technologies, Waltham, MA, USA. A Shimadzu 8201 PC spectrophotometer, a

Molecules 2015, 20
8192
Bruker DRX 400 spectrometer and a JEOL-SX 102/DA-600 mass spectrometer were used to obtain
spectral data.
3
.2. Synthesis of Amides (3a–b) and 1-Substituted-1,3-dicyclohexylurea (4) Derivatives of ATRA
The synthesis of the target compounds was achieved by dissolving a long chain fatty amine
(
(
0.011 mol), ATRA (0.011 mol) and DCC (0.011 mol) in DMSO (50 mL). A catalytic amount of DMAP
0.001 mol) was added, and the solution was stirred at room temperature. After completion of the
reaction, the reaction mixture was filtered (to remove solid dicyclohexylurea), and the filtrate was dried
under reduced pressure. The amidic derivatives 3a and 3b and the acyl urea derivative 4 of ATRA were
obtained by column chromatography using gradient elution with hexane and chloroform. The identity of
1
13
the desired compounds was confirmed using infrared (IR) and H and C nuclear magnetic resonance
NMR) spectroscopy and mass spectrometry as shown below.
(
−1
N-undecyl-retinamide (3a): Yield = 45%; IR (cm ): 3304 (N-H), 2921 (C-H asymmetric), 2847 (C-H
1
13
symmetric), 1630 (C=O); H-NMR (CDCl , δH): 7.27 (1H, s, NH), 6.74 (1H,dd, C H), 6.21 (2H, m,
3
9
12
10
16
14
6
C H, C H), 6.17 (1H, d, C H), 5.72 (1H,s, C H), 5.62 (1H, s, C H), 2.18 (2H, m, C H
2
), 2.16 (3H, s,
2
1
20
19
1
C H
3
), 1.91 (3H, s, C H
3
), 1.64 (3H, s, C H
-CH
, δC):163.6, 152.3, 140.6, 137.7, 137.4, 137.2, 130.3, 130.2, 127.5,
26.1, 125.7, 40.5, 39.30, 33.83, 32.67, 31.82, 29.71, 29.62, 29.55, 29.56, 29.51, 29.47, 29.42, 29.28,
3
), 1.56 (2H, s, O=C-NH-CH
2
), 1.51(2H, m, C H
2
), 1.49
2
(
2H, m, C H
2
), 1.46 (2H,m, O=C-NH-CH
2
2
), 1.29 (16H, br.s., chain CH
2
), 0.83 (3H, distorted t,
1
3
terminal CH
3
); C-NMR (CDCl
3
1
2
+
7.07, 22.59, 21.28, 19.00, 18.55, 14.09, 13.99; ESI-MS: [M + Na] experimental = 476.74, C31H51NO
calculated = 476.73. Anal. calcd. for C31
N, 3.06.
H51NO: C, 82.06; H, 11.31; N, 3.08. Found: C, 82.09; H, 11.35;
−
1
N-oleyl-retinamide (3b): Yield = 44%; IR (cm ): 3302 (N-H), 2927 (C-H asymm.), 2848 (C-H symm.),
1
13
9
12
1
6
2
633 (C=O); H-NMR (CDCl , δH): 7.25 (1H, s, NH), 6.79 (1H, dd, C H), 6.23 (2H, m, C H, C H),
3
1
0
16
14
6
.09 (1H, d, C H), 5.74 (1H, s, C H), 5.65 (1H, s, C H), 5.30 (2H, m, CH=CH), 2.18 (2H, m, C H
2
),
), 1.50 (2H,
-CH ), 1.23
); C-NMR (CDCl
δC):166.8, 152.3, 142.8, 140.6, 137.7, 137.2, 130.8, 130.3, 130.0, 130.0, 129.5, 126.1, 125.7, 39.53,
2
1
20
19
.21 (3H, s, C H
3
), 1.96 (4H, m, CH
2
-CH=CH-CH
2
), 1.93 (3H, s, C H
3
), 1.67 (3H, s, C H
3
1
2
m, O=C-NH-CH
2
), 1.58 (2H, m, C H
2
), 1.48 (2H, m, C H
2
), 1.48 (2H, m, O=C-NH-CH
2
2
13
(
12H, br.s., 6CH
2
), 1.12 (10H, br.s., chain 5CH
2
), 0.84 (3H, dist. t, terminal CH
3
3
,
3
2
9.30, 36.13, 32.45, 31.84, 29.70, 29.65, 29.46, 29.42, 29.31, 29.26, 29.24, 29.23, 29.11, 29.05, 28.62,
+
8.61, 27.77, 27.14, 22.62, 20.96, 19.00, 18.94, 14.04, 12.12; ESI-MS: [M + Na] experimental = 572.92,
C
38
H63NO calculated = 572.90. Anal. calcd. for C38
H63NO: C, 83.00; H, 11.57; N, 2.54. Found: C, 83.04;
H, 11.56; N, 2.58.
−
1
1
-(Retinoyl)-1,3-dicyclohexylurea (4): Yield = 46%; IR (cm ): 3310 (N-H), 2929 (C-H asymm.), 2852
1
13
(
C-H symm.), 1638 (C=O), 1227 (C-N); H NMR (CDCl , δH): 7.29 (1H, s, NH), 6.72 (1H, dd, C H),
3
9
12
10
16
14
6
.27 (2H, m, C H, C H), 6.19 (1H, d, C H), 5.79 (1H, s, C H), 5.62 (1H, s, C H), 3.84–3.80 (1H, m,
6
21
CH of C
6
H
11), 3.63–3.61 (1H, m, CH of C
6
H
11, 2.23 (2H, m, C H
2
), 2.16 (3H, s, C H
3
), 1.94 (3H, s,
20
19
1
2
13
C H
3
), 1.67 (3H, s, C H
3
), 1.54 (2H, m, C H
2
), 1.45 (2H, m, C H
2
), 1.37–1.35 (20H, m, 10CH
2
); C-NMR
(CDCl
3
, δC): 165.8, 159.3, 152.3, 140.6, 137.7, 137.2, 130.2, 130.2, 127.4, 126.1, 125.7, 50.7, 49.8,

Molecules 2015, 20
8193
3
2
9.27, 33.84, 33.37, 33.32, 32.66, 30.90, 30.74, 28.65, 28.64, 26.29, 25.76, 25.52, 25.48, 24.95, 24.85,
+
1.29, 18.97, 18.40, 12.41; ESI-MS: [M + Na] experimental = 506.77, C33
H
50
N
2
2
O calculated = 506.76.
Anal. calcd. for C33
H
50
N
2
O
2
: C, 78.22; H, 9.93; N, 5.52. Found: C, 78.26; H, 9.91; N, 5.53.
3.3. Cell Culture
MCF-7 (breast cancer), HepG2 (liver cancer) and HEK293 (embryonic kidney) cells were obtained
from American Type Culture Collection (ATCC; Manassas, VA, USA). Cells were grown in DMEM
with 10% FBS in 5% CO at 37 °C under high humidity. The trypan blue dye exclusion test [35] was
used to assess cell viability. Only cells that showed a viability of more than 98% were used in this study.
2
3
.4. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide Assay
4
Cell viability was assessed using the MTT assay [35]. In brief, 1 × 10 cells were plated in 96-well
plates and allowed to adhere to the wells overnight in a CO incubator. After treatment, MTT (10 µL)
was added to each well and incubated in a CO incubator for 4 h. Then, the supernatant was discarded,
and DMSO (200 μL) was added to each well. The absorbance was read at a wavelength of 550 nm.
2
2
3
.5. Neutral Red Uptake Assay
An NRU assay was performed according to the protocol described by Siddiqui et al. [36]. Post
treatment, the cells were washed with phosphate-buffered saline (PBS; 0.01 M; pH 7.4), and 50 µg/mL
of neutral red containing medium were added. The cells were then subjected to 3 h of incubation. The
supernatant was removed, and the cells were washed with a solution of 0.5% CH
Subsequently, a solution of 1% CH COOH and 50% EtOH was added, and the dye was extracted. The
absorbance was then read at a wavelength of 550 nm.
2
O and 1% CaCl
2
.
3
3
.6. Morphological Analysis Using Phase Contrast Microscopy
Changes in morphology were observed to determine the effect of the novel compounds in MCF-7,
HepG2 and HEK293 cells. The cells were exposed to different concentrations (10–1000 μM) of
compounds 3a, 3b and 4 for 24 h. The images were recorded using an inverted phase contrast microscope
at 20× magnification.
3
.7. Cell Cycle Analysis
Measurement of cell cycle arrest was performed using the method of Saquib et al. [37]. Briefly,
HepG2 and MCF-7 cells were exposed to various concentrations of compounds 3a, 3b and 4 for 24 h.
After centrifugation for 4 min at 1000 rpm, cells were fixed with 70% ethanol (500 µL) and were then
incubated at 4 °C for 1 h. The cells were then washed and stained using PBS (500 µL; 0.01 M; pH 7.4)
containing 50 µg/mL propidium iodide (PI), 0.5 mg/mL RNase and Triton X-100. The PI fluorescence
was measured using a Beckman Coulter flow cytometer. The results were analyzed using Coulter Epics
XL/XL-MCL, System II Software (Version 3.0, Beckman Coulter, Inc. 250 S. Kraemer Blvd. Brea, CA).

Molecules 2015, 20
8194
3.8. Apoptosis/Necrosis Assay Using Annexin V-PE and 7-Aminoactinomycin D
The assay was performed according to the manufacturer’s instructions using Annexin V-PE and
-AAD (Beckman Coulter, Marseille, Cedex 9, France) kits. Briefly, MCF-7 and HepG2 cells were
7
exposed to 250, 500 and 1000 µM of compound 3a and 10, 25 or 50 µM of 3b and 4 for 24 h. The
amount of apoptosis/necrosis in the treated HepG2 and MCF-7 cells was assessed by flow cytometry
using the detailed reported protocol [38].
3
.9. Statistical Analysis
ANOVA was used for statistical analysis, and results are expressed as the mean ± standard error of
three separate experiments. The treated and control groups were compared using the post hoc Dunnett’s
test. A value of p < 0.05 was considered statistically significant.
4
. Conclusions
This article describes the synthesis and characterization of novel amidic and acyl urea derivatives of
ATRA. The cytotoxicity measurements demonstrated a concentration-dependent reduction in the cell
viability and alteration of cellular morphology in MCF-7 and HepG2 cells, whereas, in our hands, ATRA
was not effective at concentrations ranging from 10–50 µM. The use of flow cytometry to assess cell
cycle progression and an apoptosis assay using Annexin V-PE and 7-AAD also revealed that the novel
ATRA derivatives possess substantial anticancer activity towards human cancer cell lines (MCF-7 and
HepG2). Arrest in the G /M phase of the cell cycle could be one of the mechanisms by which cell growth
2
is inhibited and apoptosis is induced by the compounds.
Supplementary Materials
Supplementary can be accessed at: http://www.mdpi.com/1420-3049/20/05/8181/s1.
Acknowledgments
This research project was supported by a grant from the “Research Centre of the Female Scientific
and Medical Colleges”, Deanship of Scientific Research, King Saud University.
Author Contributions
Maqsood Ahmed Siddiqui and Nida Nayyar Farshori conceived of and designed the experiments.
Maqsood Ahmed Siddiqui, Nida Nayyar Farshori, Quaiser Saquib, Ebtesam Saad Al-Sheddi and
Mai Mohammad Al-Oqail performed the experiments. Maqsood Ahmed Siddiqui, Nida Nayyar Farshori,
Quaiser Saquib, Ebtesam Saad Al-Sheddi, Mai Mohammad Al-Oqail and Javed Musarrat analyzed the
data. Ebtesam Saad Al-Sheddi and Abdulaziz Ali Al-Khedhairy contributed reagents/materials/analysis
tools. Maqsood Ahmed Siddiqui and Nida Nayyar Farshori wrote the paper. All authors read and
approved the final manuscript.

Molecules 2015, 20
8195
Conflict of Interest
The authors declare that they have no conflict of interest.
References
1
.
Alwan, A.; MacLean, D.R.; Riley, L.M.; d’Espaignet, E.T.; Mathers, C.D.; Stevens, G.A.;
Bettcher, D. Monitoring and surveillance of chronic non-communicable diseases: Progress and
capacity in high-burden countries. Lancet 2010, 376, 1861–1868.
2
3
.
.
Sachs, L. Growth, differentiation and the reversal of malignancy. Sci. Am. 1986, 254, 40–48.
Lan, L.; Cui, D.; Luo, Y.; Shi, B.Y.; Deng, L.L.; Zhang, G.Y.; Wang, H. Inhibitory effects of
retinoic acid on invasiveness of human thyroid carcinoma cell lines in vitro. J. Endocrinol. Investig.
2
009, 32, 731–738.
4
.
.
Lee, J.H.; Yoon, J.H.; Yu, S.J.; Chung, G.E.; Jung, E.U.; Jung, E.U.; Kim, H.Y.; Kim, B.H.;
Choi, D.H.; Myung, S.J.; et al. Retinoic acid and its binding protein modulate apoptotic signals in
hypoxic hepatocellular carcinoma cells. Cancer Lett. 2010, 295, 229–235.
5
Myga-Nowak, M.; Pacholska-Bogalska, J.; Kwasniewski, W.; Kwasniewska, A.;
Gozdzicka-Jozefiak, A. Proliferation of cells and expression of RARs, RXRs and HPV viral E6 and
E7 proteins in cervical cancer cell lines after treatment with ATRA. Ann. Agric. Environ. Med.
2
011, 18, 145–150.
6
.
.
Ginestier, C.; Wicinski, J.; Cervera, N.; Monville, F.; Finetti, P.; Bertucci, F.; Wicha, M.S.;
Birnbaum, D.; Charafe-Jauffret, E. Retinoid signaling regulates breast cancer stem cell
differentiation. Cell Cycle 2009, 8, 3297–3302.
7
Carneiro, G.; Silva, E.L.; Pacheco, L.A.; de Souza-Fagundes, E.M.; Correa, N.C.R.; de Goes, A.M.;
de Oliveira, M.C.; Ferreira, L.A.M. Formation of ion pairing as an alternative to improve
encapsulation and anticancer activity of all-trans retinoic acid loaded in solid lipid nanoparticles.
Int. J. Nanomed. 2012, 7, 6011–6020.
8
.
.
Ariga, N.; Moriya, T.; Suzuki, T.; Kimura, M.; Ohuchi, N.; Sasano, H. Retinoic acid receptor and
retinoid X receptor in ductal carcinoma in situ and intraductal proliferative lesions of the human
breast. Jpn. J. Cancer Res. 2000, 91, 1169–1176.
9
Hakimelahi, G.H.; Ly, T.W.; Yu, S.F.; Zakerinia, M.; Khalafi-Nezhad, A.; Soltani, M.N.;
Gorgani, M.N.; Chadegani, A.R.; Moosavi-Movahedi, A.A. Design and synthesis of a
cephalosporin-retinoic acid prodrug activated by a monoclonal antibody-β-lactamase conjugate.
Bioorg. Med. Chem. 2001, 9, 2139–2147.
1
0. Hakimelahi, G.H.; Zarrinehzad, M.; Jarrahpour, A.A.; Sharghi, H. Ring-open analogues of adenine
nucleoside. Aminoacylderivatives of cyclo- and acyclo-nucleosides. Helv. Chim. Acta 1987, 70,
2
19–231.
1. Bard, D.R.; Lasnitzki, I. Toxicity of anti-carcinogenic retinoids in organ culture. Br. J. Cancer 1977,
5, 115–119.
2. Gander, R.J.; Gurney, J.A. Esters of Retinoic Acid. BE Patent 0847942, 1977.
1
1
3

Molecules 2015, 20
8196
1
3. Bradley, M.O.; Webb, N.L.; Anthony, F.H.; Devanesan, P.; Witman, P.A.; Hemamalini, S.;
Chander, M.C.; Baker, S.D.; He, L.; Horwitz, S.B.; et al. Tumor targeting by covalent conjugation
of a natural fatty acid to paclitaxel. Clin. Cancer Res. 2001, 7, 3229–3238.
4. Chhikara, B.S.; St Jean, N.; Mandal, D.; Kumar, A.; Parang, K. Fatty acyl amide derivatives of
doxorubicin: Synthesis and in vitro anticancer activities. Eur. J. Med. Chem. 2011, 46, 2037–2042.
5. Chhikara, B.S.; Mandal, D.; Parang, K. Synthesis and evaluation of fatty acyl ester derivatives of
cytarabine as anti-leukemia agents. Eur. J. Med. Chem. 2010, 45, 4601–4608.
6. The Retinoids: Biology, Chemistry and Medicine, 2nd ed.; Sporn, M.B., Roberts, A.B., Goodman, D.S.,
Eds.; Raven Press: New York, NY, USA, 1994.
1
1
1
1
1
1
7. Niederreither, K.; Dollé, P. Retinoic acid in development: towards an integrated view.
Nat. Rev. Genet. 2008, 9, 541–553.
8. Smith, M.A.; Parkinson, D.R.; Cheson, B.D.; Friedman, M.A. Retinoids in cancer therapy.
J. Clin. Oncol. 1992, 10, 839–864.
9. Rhee, J.C.; Khuri, F.R.; Shin, D.M. Advances in chemoprevention of head and neck cancer.
Oncologist 2004, 9, 302–311.
2
0. Collins, M.D.; Mao, G.E. Teratology of retinoids. Annu. Rev. Pharmacol. Toxicol. 1999, 39, 399–430.
1. Sharma, R.; Sharma, R.; Verma, U.; Bhat, N.K. Drug review: Novel drugs targeting retinoic acid
receptors. JK Sci. 2005, 7, 1–2.
2
2
2
2
2. David, M.; Hodak, E.; Lowe, N.J. Adverse effects of retinoids. Med. Toxicol. Advers. Drug Exp.
1
988, 3, 273–288.
3. Silverman, A.K.; Ellis, C.N.; Voorhees, J.J. Hypervitaminosis A syndrome: A paradigm of retinoid
side effects. J. Am. Acad. Dermatol. 1987, 16, 1027–1039.
4. Boehm, M.F.; Zhang, L.; Badea, B.A.; White, S.K.; Mais, D.E.; Berger, E.; Suto, C.M.;
Goldman, M.E.; Heymanet, R.A. Synthesis and structure-activity relationships of novel retinoid X
receptor-selective retinoids. J. Med. Chem. 1994, 37, 2930–2941.
2
5. Fieser, L.F.; Fieser, M. Reagents for Organic Synthesis, 1st ed.; John Wiley and Sons Inc.: London,
UK, 1967.
2
6. Nogueira, D.R.; Mitjans, M.; Infante, M.R.; Vinardell, M.P. Comparative sensitivity of tumor and
non-tumor cell lines as a reliable approach for in vitro cytotoxicity screening of lysine-based
surfactants with potential pharmaceutical applications. Int. J. Pharm. 2011, 420, 51–58.
7. Nicoletti, I.; Migliorati, G.; Pagliacci, M.C.; Grignani, F.; Riccardi, C. A rapid and simple method
for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol.
Methods 1991, 139, 271–279.
2
2
8. Ravi, S.; Chiruvella, K.K.; Rajesh, K.; Prabhu, V.; Raghavan, S.C. 5-Isopropylidene-3-ethyl
rhodanine induce growth inhibition followed by apoptosis in leukemia cells. Eur. J. Med. Chem.
2
010, 45, 2748–2752.
2
3
3
9. Ferreira, C.G.; Epping, M.; Kruyt, F.A.; Giaccone, G. Apoptosis: Target of cancer therapy.
Clin. Cancer Res. 2002, 8, 2024–2034.
0. Konopa, J. G2 block induced by DNA crosslinking agents and its possible consequence.
Biochem. Pharmacol. 1998, 37, 2303–2309.
1. Tsao, Y.P.; D’Arpa, P.; Liu, L.F. The involvement of active DNA synthesis in camptothecin-induced
G2 arrest: Altered regulation of p34cdc2/cyclin B. Cancer Res. 1992, 52, 1823–1829.

Molecules 2015, 20
8197
3
3
2. Fadok, V.A.; Voelker, D.R.; Campbell, P.A.; Cohen, J.J.; Bratton, D.L.; Henson, P.M. Exposure of
phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and
removal by macrophages. J. Immunol. 1992, 7, 2207–2216.
3. Martin, S.J; Reutelingsperger, C.P.M.; McGahon, A.J.; Rader, J.; van Schie, R.C.A.A.;
LaFace, D.M.; Green, D.R. Early redistribution of plasma membrane phosphatidylserine is a general
feature of apoptosis regardless of the initiating stimulus. Inhibition by over expression of Bcl-2 and Abl.
J. Exp. Med. 1995, 182, 1545–1557.
3
3
4. Diaz, C.; Schroit, A. Role of translocases in the generation of phosphatidylserine asymmetry.
J. Membr. Biol. 1996, 151, 1–9.
5. Siddiqui, M.A.; Singh, G.; Kashyap, M.P.; Khanna, V.K.; Yadav, S.; Chandra, D.; Pant, A.B.
Influence of cytotoxic doses of 4-hydroxynonenal on selected neurotransmitter receptors in PC-12
cells. Toxicol. In Vitro 2008, 22, 1681–1688.
3
6. Siddiqui, M.A.; Kashyap, M.P.; Kumar, V.; Al-Khedhairy, A.A.; Musarrat, J.; Pant, A.B.
Protective potential of trans-resveratrol against 4-hydroxynonenal induced damage in PC12 cells.
Toxicol. In Vitro 2010, 6, 1592–1598.
3
7. Saquib, Q.; Al-Khedhairy, A.A.; Ahmad, J.; Siddiqui, M.A.; Dwivedi, S.; Khan, S.T.; Musarrat, J.
Zinc ferrite nanoparticles activate IL-1b, NFKB1, CCL21 and NOS2 signaling to induce
mitochondrial dependent intrinsic apoptotic pathway in WISH cells. Toxicol. Appl. Pharmacol.
2
013, 273, 289–297.
3
8. Saquib, Q.; Musarrat, J.; Siddiqui; M.A.; Dutta, S.; Dasgupta, S.; Giesy, J.P.; Al-Khedhairy, A.A.
Cytotoxic and necrotic responses in human amniotic epithelial (WISH) cells exposed to
organophosphate insecticide phorate. Mutat. Res. 2012, 744, 125–134.
Sample Availability: Samples of the compounds 3a–b and 4 are available from the authors.
©
2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
http://creativecommons.org/licenses/by/4.0/).
(